1 / 16

Eisai Pharmaceutical Performance and SWOT Analysis (2004-2016)

This comprehensive analysis examines Eisai's prescription pharmaceutical performance from 2004 to 2016, highlighting key sales figures, growth rates, and market dynamics. The SWOT analysis reveals strengths like the successful launch of the cancer drug Halaven and opportunities for growth in emerging markets. However, it also identifies weaknesses, including over-reliance on blockbuster drugs and threats from patent expirations. This report offers valuable insights for stakeholders looking to understand Eisai's market position and future growth trajectory.

avani
Télécharger la présentation

Eisai Pharmaceutical Performance and SWOT Analysis (2004-2016)

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. quality data expert analysis intuitive delivery the home ofBusiness Intelligence © Datamonitor © Datamonitor

  2. PharmaVitae: Eisai DMHC00068-031 Slidepack 12/11 the home ofBusiness Intelligence quality data expert analysis intuitive delivery

  3. Eisai prescription pharmaceutical performance, sales ($m) and growth rate (%), 2004–16

  4. SWOT analysis of Eisai Strengths Weaknesses • Successful launch of breast cancer drug Halaven to improve Eisai’s presence in the fast-growth US oncology market. • Japanese license to commercialize the monoclonal antibody Humira will drive significant gains, mainly driven by indication expansions. • High reliance on key blockbuster brands, Aricept and Aciphex, that are highly exposed to generic competition. • Modest potential of core portfolio beyond Humira leaves Eisai’s growth trajectory subject to risks of attrition associated with its launch portfolio as well as to sales losses from its expiry portfolio. Threats Opportunities • Sales growth from RoW/emerging markets. • Further acquisitions to expand current capabilities and product portfolio. • Japanese healthcare reforms could impact domestic revenue streams.

  5. Current corporate structure Prescription pharmaceuticals OTC Generics Diagnostics

  6. Eisai prescription pharmaceutical performance, sales ($m) and growth rate (%), 2004–16

  7. Key product sales ($m), 2004–16

  8. 10,000 -$1,297m 9,000 8,000 7,000 6,000 Sales ($m) 5,000 4,000 3,000 2,000 1,000 0 04 05 06 07 08 09 10 11 12 13 14 15 16 Rest of portfolio Aricept Pariet/Aciphex Aricept and Pariet/Aciphex sales ($m), 2010-16

  9. Eisai key product growth drivers and resistors ($m), 2004–10

  10. Eisai key product growth drivers and resistors ($m), 2010–16

  11. Eisai prescription pharmaceutical sales by therapy area ($m), 2004–16

  12. Eisai prescription pharmaceutical sales by geographic region ($m), 2004–16

  13. Eisai launch, core and expiry configuration, sales ($m), 2010–16 +1,840 +125 -3,329 8,227 +66 6,930

  14. Eisai prescription pharmaceutical sales by molecule type ($m), 2004–16

  15. Eisai prescription pharmaceutical sales by source of product ($m), 2004–16

  16. quality data expert analysis intuitive delivery the home ofBusiness Intelligence © Datamonitor © Datamonitor

More Related